Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149925 (
small cell lung cancer
)
6,491
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MYC stimulates both metabolism and protein synthesis, but it is unknown how cells coordinate these complementary programs. Previous work reported that in a subset of
small cell lung cancer
(
SCLC
) cell lines, MYC activates guanosine triphosphate (GTP) synthesis and results in sensitivity to inhibitors of the GTP synthesis enzyme inosine monophosphate dehydrogenase (IMPDH). Here we demonstrated that primary MYCHigh human
SCLC
tumors also contain abundant guanosine nucleotides. We also found that elevated MYC in SCLCs with acquired chemoresistance rendered these otherwise recalcitrant tumors dependent on IMPDH. Unexpectedly, our data indicated that IMPDH links the metabolic and protein synthesis outputs of oncogenic MYC. Co-expression analysis placed IMPDH within the MYC-driven ribosome program, and GTP depletion prevented RNA Polymerase I (Pol I) from localizing to ribosomal DNA. Furthermore, the GTPases
GPN1
and GPN3 were upregulated by MYC and directed Pol I to ribosomal DNA. Constitutively GTP-bound
GPN1
/3 mutants mitigated the effect of GTP depletion on Pol I, protecting chemoresistant
SCLC
cells from IMPDH inhibition. GTP therefore functions as a metabolic gate tethering MYC-dependent ribosome biogenesis to nucleotide sufficiency through
GPN1
and GPN3. IMPDH dependence is a targetable vulnerability in chemoresistant, MYCHigh
SCLC
.
...
PMID:Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small cell lung cancer. 3307 28